Company profile: Greenphire
1.1 - Company Overview
Company description
- Provider of technology-based clinical payment, travel logistics, and financial lifecycle management solutions for global clinical trials, serving pharmaceutical sponsors, CROs and research sites. Products include ClinCard for participant payments, ConneX for travel coordination, eClinicalGPS for global financial management, and EnvisiX for budgeting, with data and workflow automation from budgeting through analysis.
Products and services
- EClinicalGPS: Architects a global-scale platform that streamlines financial management and transactions across clinical trials for sponsors, CROs, and sites, enabling data and workflow automation from budgeting through analysis
- ClinCard: Produces a regulated participant payment system that facilitates clinical trial financial transactions, driving seamless, regulated disbursements for global pharmaceutical sponsors, CROs, and research sites
- ConneX: Delivers a workflow-automated travel management service that coordinates logistics for clinical trial participants to ensure seamless participation in global studies for sponsors, CROs, and sites
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Greenphire
Warp Drive Bio
HQ: United States
Website
- Description: Provider of a proprietary genomic search engine and customized search queries that reveal hidden natural products on the basis of their distinctive genomic signature.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Warp Drive Bio company profile →
Formation Bio
HQ: United States
Website
- Description: Provider of a drug development platform and AI-driven tools to accelerate and optimize clinical trials and drug discovery. Offerings include an end-to-end platform leveraging proprietary technology, a clinical trial engine to improve recruitment, data collection and monitoring, and a universal data platform centralizing clinical data for rapid application creation and trial design.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Formation Bio company profile →
LabCentral
HQ: United States
Website
- Description: Provider of a facility (LabCentral 238) offering on-site capacities for collaborative cell therapy programs in regenerative medicine and immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LabCentral company profile →
BenchSci
HQ: Canada
Website
- Description: Provider of biology-specific multimodal AI for scientific accuracy and scalable, enterprise-grade software to accelerate drug discovery and biomedical research, featuring ASCEND, a GenAI assistant that understands disease biology across therapeutic areas; a Data Foundation with access to comprehensive biomedical datasets (papers, patents, third-party data); and secure integrations of internal pharmaceutical data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BenchSci company profile →
Silicon Therapeutics
HQ: United States
Website
- Description: Provider of fully integrated drug design, research and development using a physics-driven approach coupled to chemistry and biology R&D, with a pipeline including VTAMA (Tapinarof) for plaque psoriasis; Batoclimab for autoimmune diseases (MG, TED, CIDP, Graves' Disease); IMVT-1402 (Phase 1) subcutaneous injection; Brepocitinib for dermatomyositis and non-infectious uveitis (Phase 3 for some applications); and Namilumab for sarcoidosis (Phase 2).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silicon Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Greenphire
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Greenphire
2.2 - Growth funds investing in similar companies to Greenphire
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Greenphire
4.2 - Public trading comparable groups for Greenphire
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →